[Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]

Warmuth M, Fischer S
Record ID 32012000777
German
Authors' objectives: Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates the following indications of RFA for the treatment of benign and malignant tumors of the urogenital tract: renal cell carcinoma, prostate cancer and uterine leiomyoma.
Authors' recommendations: According to GRADE, the quality of evidence is very low due to the uncontrolled study design of the included case series and the inadequate control group of the included RCT (HIFU) of RFA for the treatment of uterine leiomyomas. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to surgical resection for the treatment of urogenital tumors. Currently, the inclusion into the hospital benefit catalogue is not recommended.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Catheter Ablation
  • Prostatic Neoplasms
  • Uterine Neoplasms
  • Kidney Neoplasms
  • Radiofrequency Ablation
  • Leiomyoma
  • Myoma
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.